Richard William Scalzo Sells 1,455 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Richard William Scalzo also recently made the following trade(s):

• On Wednesday, September 18th, Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock. The stock was sold at an average price of $34.55, for a total value of $48,024.50.

Dyne Therapeutics Price Performance

DYN opened at $25.61 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $10.80 and a 1-year high of $47.45. The stock has a market cap of $2.61 billion, a P/E ratio of -7.19 and a beta of 1.09. The stock’s 50 day simple moving average is $30.53 and its 200 day simple moving average is $35.24.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. RTW Investments LP raised its position in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after purchasing an additional 431,503 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after buying an additional 2,189,339 shares in the last quarter. RA Capital Management L.P. grew its holdings in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares during the last quarter. Finally, State Street Corp increased its position in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DYN shares. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Guggenheim raised their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $50.82.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.